{"version":"1.0","type":"link","title":"Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.","author_name":"Goetze TO 외","author_url":"https://prs-insight.online/author/Goetze%20TO","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/157697","thumbnail_width":1200,"thumbnail_height":630}